Mycosis Fungoides News and Research

RSS
New first-line treatment for peripheral T-cell lymphoma approved by FDA

New first-line treatment for peripheral T-cell lymphoma approved by FDA

FDA approves drug for rare, hard-to-treat types of non-Hodgkin lymphoma

FDA approves drug for rare, hard-to-treat types of non-Hodgkin lymphoma

Bielefeld University launches five new medical research projects

Bielefeld University launches five new medical research projects

NCCN educational resources provide insight for patients with Mycosis Fungoides

NCCN educational resources provide insight for patients with Mycosis Fungoides

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Study exposes racial differences in the treatment of lymphoma

Study exposes racial differences in the treatment of lymphoma

FDA grants marketing approval for VALCHLOR gel for treatment of early stage CTCL

FDA grants marketing approval for VALCHLOR gel for treatment of early stage CTCL

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

EMA grants Orphan Drug Designation to Ceptaris' chlormethine gel for treatment of CTCL

EMA grants Orphan Drug Designation to Ceptaris' chlormethine gel for treatment of CTCL

Yaupon seeks FDA marketing approval of mechlorethamine gel for mycosis fungoides

Yaupon seeks FDA marketing approval of mechlorethamine gel for mycosis fungoides

Initial data from COMPLETE study on peripheral T-cell lymphoma presented at ICML 2011

Initial data from COMPLETE study on peripheral T-cell lymphoma presented at ICML 2011

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Elorac's naloxone lotion receives FDA Orphan Drug Designation for pruritus associated with mycosis fungoides

Elorac's naloxone lotion receives FDA Orphan Drug Designation for pruritus associated with mycosis fungoides

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

TenX Biopharma recommences enrollment in suspended Phase III trial for cutaneous T-cell lymphoma

TenX Biopharma recommences enrollment in suspended Phase III trial for cutaneous T-cell lymphoma

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

NCCN Guidelines adds ofatumumab and romidepsin as therapy options for CLL

NCCN Guidelines adds ofatumumab and romidepsin as therapy options for CLL

Genmab's HuMax-CD4 receives U.S. orphan drug designation

Genmab's HuMax-CD4 receives U.S. orphan drug designation